Centessa Pharmaceuticals PLCNASDAQ:CNTA
- LAST PRICE8.9300
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots3.5900/ 1
- Ask / Lots12.9800/ 1
- Open / Previous Close0.0000 / 8.9300
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CNTA |
|---|---|---|
| 09:32 ET | 951 | 9.11 |
| 09:36 ET | 1200 | 9.25 |
| 09:38 ET | 200 | 9.26 |
| 09:39 ET | 500 | 9.25 |
| 09:45 ET | 100 | 9.16 |
| 09:52 ET | 100 | 9.25 |
| 09:54 ET | 38843 | 9.26 |
| 09:56 ET | 100 | 9.38 |
| 09:57 ET | 4324 | 9.235 |
| 09:59 ET | 2800 | 9.3 |
| 10:01 ET | 300 | 9.27 |
| 10:03 ET | 100 | 9.2 |
| 10:06 ET | 100 | 9.3 |
| 10:08 ET | 100 | 9.21 |
| 10:10 ET | 15983 | 9.24 |
| 10:12 ET | 500 | 9.23 |
| 10:14 ET | 100 | 9.19 |
| 10:15 ET | 487 | 9.18 |
| 10:17 ET | 1739 | 9.19 |
| 10:19 ET | 1700 | 9.25 |
| 10:21 ET | 1500 | 9.28 |
| 10:24 ET | 1000 | 9.27 |
| 10:26 ET | 1200 | 9.21 |
| 10:28 ET | 1995 | 9.245 |
| 10:30 ET | 1048 | 9.25 |
| 10:32 ET | 2730 | 9.25 |
| 10:33 ET | 1817 | 9.2566 |
| 10:35 ET | 300 | 9.23 |
| 10:39 ET | 1403 | 9.23 |
| 10:42 ET | 200 | 9.15 |
| 10:44 ET | 1100 | 9.175 |
| 10:46 ET | 3329 | 9.07 |
| 10:48 ET | 200 | 9.07 |
| 10:50 ET | 300 | 9.02 |
| 10:51 ET | 100 | 9.025 |
| 10:53 ET | 100 | 9.02 |
| 10:55 ET | 1296 | 9.01 |
| 10:57 ET | 285 | 9 |
| 11:00 ET | 6782 | 9.12 |
| 11:06 ET | 1300 | 9.065 |
| 11:11 ET | 400 | 9 |
| 11:15 ET | 700 | 8.91 |
| 11:18 ET | 4434 | 8.9 |
| 11:20 ET | 2000 | 9.03 |
| 11:22 ET | 100 | 8.995 |
| 11:24 ET | 100 | 9.04 |
| 11:26 ET | 700 | 8.9925 |
| 11:27 ET | 400 | 8.955 |
| 11:29 ET | 200 | 9 |
| 11:31 ET | 100 | 9 |
| 11:33 ET | 808 | 8.99 |
| 11:36 ET | 100 | 9.02 |
| 11:38 ET | 2800 | 8.975 |
| 11:40 ET | 3199 | 9.01 |
| 11:44 ET | 100 | 9.06 |
| 11:47 ET | 100 | 9.02 |
| 11:49 ET | 300 | 9.03 |
| 11:51 ET | 700 | 9.02 |
| 11:54 ET | 1602 | 9.03 |
| 11:56 ET | 200 | 9 |
| 12:00 ET | 100 | 9.03 |
| 12:02 ET | 100 | 9.005 |
| 12:03 ET | 13552 | 9.102 |
| 12:16 ET | 100 | 9.19 |
| 12:18 ET | 700 | 9.21 |
| 12:21 ET | 1647 | 9.18 |
| 12:27 ET | 904 | 9.18 |
| 12:32 ET | 710 | 9.17 |
| 12:38 ET | 703 | 9.19 |
| 12:39 ET | 1411 | 9.185 |
| 12:41 ET | 1001 | 9.2 |
| 12:45 ET | 703 | 9.2 |
| 12:50 ET | 207 | 9.14 |
| 12:54 ET | 100 | 9.145 |
| 12:59 ET | 417 | 9.19 |
| 01:01 ET | 100 | 9.195 |
| 01:08 ET | 3448 | 9.31 |
| 01:10 ET | 1579 | 9.25 |
| 01:12 ET | 100 | 9.26 |
| 01:14 ET | 400 | 9.25 |
| 01:17 ET | 200 | 9.22 |
| 01:19 ET | 2183 | 9.14 |
| 01:21 ET | 100 | 9.145 |
| 01:24 ET | 100 | 9.165 |
| 01:26 ET | 200 | 9.14 |
| 01:28 ET | 100 | 9.14 |
| 01:32 ET | 9733 | 9.09 |
| 01:35 ET | 2203 | 9.09 |
| 01:39 ET | 578 | 9.14 |
| 01:42 ET | 100 | 9.15 |
| 01:44 ET | 200 | 9.15 |
| 01:46 ET | 300 | 9.16 |
| 01:50 ET | 100 | 9.16 |
| 01:51 ET | 200 | 9.18 |
| 01:57 ET | 2385 | 9.215 |
| 02:00 ET | 200 | 9.205 |
| 02:04 ET | 707 | 9.23 |
| 02:09 ET | 2900 | 9.2 |
| 02:11 ET | 210 | 9.23 |
| 02:18 ET | 2700 | 9.265 |
| 02:20 ET | 3313 | 9.22 |
| 02:22 ET | 100 | 9.24 |
| 02:24 ET | 1001 | 9.225 |
| 02:26 ET | 165 | 9.2 |
| 02:29 ET | 100 | 9.17 |
| 02:31 ET | 100 | 9.165 |
| 02:33 ET | 900 | 9.12 |
| 02:36 ET | 400 | 9.08 |
| 02:38 ET | 200 | 9.09 |
| 02:40 ET | 100 | 9.14 |
| 02:42 ET | 303 | 9.08 |
| 02:44 ET | 100 | 9.04 |
| 02:45 ET | 200 | 9.05 |
| 02:51 ET | 922 | 9.025 |
| 02:56 ET | 690 | 9.08 |
| 03:02 ET | 1239 | 9.06 |
| 03:03 ET | 100 | 9.07 |
| 03:05 ET | 300 | 9.06 |
| 03:09 ET | 1240 | 9.01 |
| 03:12 ET | 1300 | 9.06 |
| 03:14 ET | 100 | 9.07 |
| 03:16 ET | 200 | 9.01 |
| 03:20 ET | 2000 | 9.01 |
| 03:21 ET | 100 | 9.01 |
| 03:23 ET | 400 | 9.01 |
| 03:25 ET | 2541 | 9.09 |
| 03:27 ET | 642 | 9.1 |
| 03:30 ET | 300 | 9.09 |
| 03:32 ET | 200 | 9.07 |
| 03:34 ET | 100 | 9.085 |
| 03:38 ET | 3380 | 9.05 |
| 03:39 ET | 1842 | 9.01 |
| 03:41 ET | 500 | 9 |
| 03:43 ET | 1603 | 9 |
| 03:45 ET | 3039 | 9 |
| 03:48 ET | 4324 | 9.06 |
| 03:50 ET | 2500 | 9.05 |
| 03:52 ET | 1345 | 9.04 |
| 03:54 ET | 1698 | 9.01 |
| 03:56 ET | 10740 | 9 |
| 03:57 ET | 4509 | 9.03 |
| 03:59 ET | 9542 | 8.93 |
Apr 23, 2024
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares, from 9:36PM ET on Tuesday Apr 23, 2024 by Dow Jones
9:36PM ET on Tuesday Apr 23, 2024 by Dow JonesPress Release: Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares, from 4:17PM ET on Tuesday Apr 23, 2024 by Dow Jones
4:17PM ET on Tuesday Apr 23, 2024 by Dow JonesCentessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares, from 4:17PM ET on Tuesday Apr 23, 2024 by Dow Jones
4:17PM ET on Tuesday Apr 23, 2024 by Dow Jones
Apr 22, 2024
Apr 1, 2024
DJ Centessa Pharmaceuticals Is Maintained at Outperform by BMO Capital, from 12:36PM ET on Monday Apr 01, 2024 by Dow Jones
12:36PM ET on Monday Apr 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Centessa Pharmaceuticals PLC | 895.7M | -5.7x | --- |
Praxis Precision Medicines Inc | 875.5M | -2.2x | --- |
SS Innovations International Inc | 851.9M | -38.6x | --- |
ALX Oncology Holdings Inc | 851.9M | -4.5x | --- |
Cassava Sciences Inc | 939.7M | -9.4x | --- |
Immunome Inc | 851.2M | -4.3x | --- |
Company Information
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company's advanced product candidate, SerpinPC, is a subcutaneously administered inhibitor of activated protein C (APC) being developed as a potential treatment for hemophilia. Leveraging its LockBody technology, it is developing an approach to selectively drive potent effector function activity, such as CD47 or CD3, into the tumor microenvironment (TME) while avoiding systemic toxicity. Its first LockBody product candidate, LB101, is a conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody used in solid tumors. Its other programs consist of earlier-stage preclinical assets, including ORX750, an orally administered, selective Orexin Receptor-2 (OX2R) agonist for the treatment of narcolepsy (NT1) with potential expansion into other sleep disorders, and MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH).
Contact Information
- Headquarters
- 3Rd Floor, 1 Ashley RoadALTRINCHAM, United Kingdom WA14 2DT
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Francesco de Rubertis
- Chief Executive Officer, Director
- Saurabh Saha
- Chief Financial Officer
- Gregory Weinhoff
- Chief People Officer
- Karen Anderson
- Executive Vice President and Chairman of Development
- Antoine Yver
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $895.7M |
|---|---|
Revenue (TTM) | $6.9M |
Shares Outstanding | 100.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.57 |
Book Value | $2.39 |
P/E Ratio | -5.7x |
Price/Sales (TTM) | 130.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,499.39% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
